Trade Summary

2 days ago, Callos Andrew, serving as EVP, Chief Commercial Officer at Cytokinetics Inc (CYTK), sold 1,809 shares at $62.44 per share, for a total transaction value of $112,954.00. Following this transaction, Callos Andrew now holds 51,353 shares of CYTK.

This sale represents a 3.00% decrease in Callos Andrew's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Monday, December 29, 2025 and publicly disclosed via SEC Form 4 filing on Tuesday, December 30, 2025, 1 day after the trade was made.

Cytokinetics Inc operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.